The IPO Buzz: CG Oncology Prices Upsized IPO at $19 – $1 Above …

T wice: Bladder cancer biotech CG Oncology (CGON) upsized its IPO for the second time this week – by pricing 20.0 million shares at $19.00 – $1.00 above the top of its range – to raise …

CouponFollow Extension

$19
OFF

The IPO Buzz: CG Oncology Prices Upsized IPO At $19 – $1 Above …

4 weeks from now

T wice: Bladder cancer biotech CG Oncology (CGON) upsized its IPO for the second time this week – by pricing 20.0 million shares at $19.00 – $1.00 above the top of its range – to raise …

iposcoop.com

$19
OFF

Bladder Cancer Biotech CG Oncology Prices Further Upsized IPO …

4 weeks from now

Jan 25, 2024 · Bladder cancer biotech CG Oncology prices further upsized IPO above the range at $19 January 25, 2024 CG Oncology, a Phase 3 biotech developing an oncolytic …

renaissancecapital.com

0%
OFF

CG Oncology (CGON) Prices Upsized 20M Share IPO At $19/sh

4 weeks from now

Jan 25, 2024 · Price: $0.00 --0% Join SI Premium – FREE CG Oncology, Inc. (Nasdaq: CGON ) today announced the pricing of its upsized initial public offering of 20,000,000 shares of its …

streetinsider.com

$380
OFF

CG Oncology Prices Larger-than-expected $380M IPO In Hopeful …

4 weeks from now

Jan 24, 2024 · CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech The sector’s first IPO of 2024 was in keeping with a recent investment trend favoring …

biopharmadive.com

$1.75
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

4 weeks from now

Jan 25, 2024 · The Irvine, California-based company debuted at $29 per share on the Nasdaq, above the upsized offer price of $19 apiece. The firm sold 20 million shares in its offering and …

reuters.com

$19.00
OFF

CG Oncology Inc. | IPOScoop

4 weeks from now

(Note: CG Oncology, Inc. upsized its IPO at pricing – to 20.0 million shares – up from its recently increased size of 17.0 million shares – and priced the IPO at $19.00 – $1.00 above the top of …

iposcoop.com

$437
OFF

CG Oncology Announces Upsized $437 Million IPO - Cooley

4 weeks from now

New York – January 29, 2024 – Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential …

cooley.com

$1.75
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market ... Adds background and context on IPO market in paragraphs 2-3 ... above the …

nasdaq.com

96%
OFF

CG Oncology IPO Rockets 96% In Sign Of Pent-up Deal Demand

4 weeks from now

Jan 25, 2024 · Irving, Calif.-based CG Oncology's stock (CGON) closed its first day of trading at $37.17 a share, up 95.6% from its $19 IPO price and well above its opening trade of $29 a share.

morningstar.com

$380
OFF

CG Oncology Brings In $380M From First Biotech IPO Of 2023

4 weeks from now

Jan 25, 2024 · Even before that, the $380 million haul puts CG Oncology at the very top end of the IPO scale when judged by 2023 standards. In fact, the only biotech to exceed that level …

fiercebiotech.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

yahoo.com

FAQs about The IPO Buzz: CG Oncology Prices Upsized IPO at $19 – $1 Above … Coupon?

Will CG oncology raise $100 million in a public offering?

IRVINE, Calif.-- (BUSINESS WIRE)--CG Oncology Announces Pricing of Upsized Initial Public Offering. CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. ...

Does CG oncology have a biotech IPO?

CG Oncology's initial public offering (IPO), the first by a biotech firm this year, sets the stage for other healthcare companies such as KKR-backed BrightSpring Health Services and Moderna-backed Metagenomi. Investment in biotech companies over the past two years has been a fraction of historical levels. ...

When will CG oncology's public offering close?

The offering is expected to close on January 29, 2024, subject to the satisfaction of customary closing conditions. In addition, CG Oncology has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. ...

Will CG IPO a biotech company in 2024?

The offering is the biotechnology sector’s first of 2024 and could be the start of an early IPO run. CG is one of five biotech companies to reveal IPO plans since January. One other, ArriVent Biopharma, is expected to price an offering this week. Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. ...

How much money will CG oncology's stock make?

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $380.0 million. CG Oncology’s common stock is expected to begin trading on the Nasdaq Global Select Market on January 25, 2024 under the ticker symbol "CGON." ...

Is CG a start of an early IPO run?

Shares will begin trading Thursday on the Nasdaq stock exchange under the ticker symbol “CGON.” The offering is the biotechnology sector’s first of 2024 and could be the start of an early IPO run. CG is one of five biotech companies to reveal IPO plans since January. One other, ArriVent Biopharma, is expected to price an offering this week. ...